With the slowdown in world economic growth, the Proto-Oncogene Drug industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Proto-Oncogene Drug market size to maintain the average annual growth rate of XXX from XXX million $ in 2014 to XXX million $ in 2019, Stratagem Market Insights analysts believe that in the next few years, Proto-Oncogene Drug market size will be further expanded, we expect that by 2026, The market size of the Proto-Oncogene Drug will reach XXX million $.
A proto-oncogene is a normal gene found in the cell and is involved in producing a protein involved in cell growth, division, and other processes in the cell. A mutation in proto-oncogene can turn the cell into a malfunctioning gene called an oncogene, which is a major cause of cancer.
Increasing prevalence of cancer is expected to boost growth of the global proto-oncogene drugs market over the forecast period. For instance, according to the World Health Organization, around 18.1 million new cases and 9.6 million deaths were registered due to cancer worldwide in 2018. Moreover, R&D in proto-oncogenes is also expected to aid in growth of the market. For instance, in February 2019, researchers from Al-Farabi Kazakh National University (Kazakhstan) and University of Pittsburgh Medical Center (U.S.) reported testing the c-myc proto-oncogene for its involvement in the mechanism of NK cell abnormalities in patients with lung and gastric cancer.
Increasing investment and funding in R&D of cancer and cancer treatment is expected to offer lucrative growth opportunities for players in the global proto-oncogene drugs market. For instance, according to the National Cancer Research Institute (NCRI), cancer research funding by NCRI partners reached around US$ 750 million in 2018/19. Similarly, in February 2020, AmorChem collaborated with Univalor, the Montreal Clinical Research Institute and McGill University for investment in R&D in c-Myc, a proto-oncogene implicated in over 50% of all human cancers.
However, high cost of and lack of awareness regarding proto-oncogene drugs is expected to hinder growth of the global proto-oncogene drugs market.
Major players in the market are focused on conducting clinical trials to expand their product portfolio. For instance, Pfizer, Inc., in collaboration with OxOnc Development LP, is conducting Phase II clinical trial for assessing the efficacy and safety of crizotinib in patients with advanced anaplastic lymphoma kinase-negative non-small cell lung cancer harboring a translocation or inversion involving the c-ROS oncogene (ROS1) locus. The study is expected to be complete in April 2020.
Major players in the market are also focused on product approval and launch to expand their product portfolio. For instance, in August 2019, Genentech, Inc., is a biotechnology corporation, received the U.S. Food and Drug Administration (FDA)’s accelerated approval for its Rozlytrek (entrectinib) — an inhibitor of tropomyosin receptor tyrosine kinases (TRK), proto-oncogene tyrosine-protein kinase ROS1 (ROS1), and anaplastic lymphoma kinase (ALK), for the treatment of non-small cell lung cancer.
Key Takeaways:
- Increasing prevalence of cancer to augment growth of the global proto-oncogene drugs market over the forecast period
- High cost of proto-oncogene drugs to hamper growth of the market
- Major players operating in the global proto-oncogene drugs market include, ARIAD Pharmaceuticals, AstraZeneca, Bayer Healthcare, Bristol-Myers Squibb, ChemGenex Pharmaceuticals, Dexa Medica, Eisai Pharmaceuticals, Exelixis, GlaxoSmithKline, Novartis, Onyx Pharmaceuticals, Plexxikon, and Pfizer
This Report covers the manufacturers' data, including: shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume and value, as well as price data.
Besides, the report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.
Section 1: Definition
Section (2 3): Manufacturer Detail
╼ ARIAD Pharmaceuticals
╼ AstraZeneca
╼ Bayer Healthcare
╼ Bristol-Myers Squibb
╼ ChemGenex Pharmaceuticals
╼ Dexa Medica
╼ Eisai Pharmaceuticals
╼ Exelixis
╼ GlaxoSmithKline
╼ Novartis
╼ Onyx Pharmaceuticals
╼ Plexxikon
╼ Pfizer
Section 4: Region Segmentation
╼ North America Country (United States, Canada)
╼ South America
╼ Asia Country (China, Japan, India, Korea)
╼ Europe Country (Germany, UK, France, Italy)
╼ Other Country (Middle East, Africa, GCC)
Section (5 6 7): Type Segmentation
Product Type Segmentation ➟
╼ Axitinib (Inlyta)
╼ Ponatinib (Iclusig)
╼ Imatinib (Gleevec)
╼ Sunitinib (Sutent)
╼ Pazopanib (Votrient)
Industry Segmentation ➟
╼ Clinic
╼ Hospital
Channel (Direct Sales, Distributor) Segmentation
Section 8: Trend (2019-2026)
Section 9: Product Type Detail
Section 10: Downstream Consumer
Section 11: Cost Structure
Section 12: Conclusion
Request Discount 
Inquire Before Buy
